研究助技師
中央研究院生醫轉譯研究中心
人類治療性抗體核心設施 計畫主持人
Office: 轉譯中心 B344 (國家生技研究園區)
Office TEL: (02)7750-5844
Lab TEL: (02)7750-5800 #2301 #2313
E-mail: reminlu@sinica.edu.tw
專業摘要
14年以上人類抗體工程研發經驗
17篇文章發表於學術期刊或專書以及11項國際專利
6 項抗體相關專利或技術方法技轉業界
2項抗體相關產品獲得台灣食藥署專案製造許可(新冠肺炎抗原快篩與雙抗體快篩)
2 年抗體新藥的業界前臨床階段開發經驗
經歷
2019 – 2021 特殊技術人員兼研發組長 中央研究院 生醫轉譯研究中心 人類治療性抗體核心設施
2015 - 2019 特殊技術人員 中央研究院 細胞與個體生物學研究所
2013 - 2015 研究員 中天生物科技集團 新藥開發中心
2011 - 2013 院聘博士後研究學者 中央研究院 細胞與個體生物學研究所
2002 - 2006 研究助理 (國防役) 中央研究院 生物醫學研究所
學歷
2006 - 2011 博士 國防醫學院 生命科學研究所(中研院細生所)
2000 - 2002 碩士 台灣大學醫學院 病理學研究所
1996 - 2000 學士 慈濟醫學院 醫事技術學系
1. 噬菌體顯現人類抗體庫建立
2. 噬菌體顯現人類抗體篩選技術
3. 抗體工程-抗體重組生產與純化
4. 抗體人源化技術
5. 抗原決定位鑑定
6. 蛋白質工程-重組生產與純化
7. 標的配體藥物傳輸系統
榮譽事項
2015 中央研究院2015年優勢研究領域-癌症疫苗與抗體新藥研發
2013 中央研究院細生所 學術論文海報比賽 優勝
2012 中央研究院100年度重要研究成果
2011 第8屆國家新創獎 學生組 第三名
2011 第19屆細胞與分子生物新知研討會 優秀壁報論文獎
2010 第37屆 國軍軍醫學術研討會海報競賽 銅牌獎
2010 國防醫學院生命科學研究所 生醫研討會 博士生壁報論文獎
2003 國際基因體學,蛋白質體學幹細胞與生醫科技研討會 傑出壁報論文獎
2003 第18屆生物醫學年會 優秀壁報論文獎
2000 醫事檢驗師國家專技高考及格
1996-1998 慈濟醫學院 慈濟公費獎學金
著作目錄
1. Yu-Chyi Hwang*, Ruei-Min Lu*, Shih-Chieh Su, Pao-Yin Chiang, Shih-Han Ko, Feng-Yi Ke, Kang-Hao Liang, Tzung-Yang Hsieh & Han-Chung Wu. (2022) Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science 29, 1. https://doi.org/10.1186/s12929-021-00784-w (*Co-First Author)
2. Ruei-Min Lu, Shih-Han Ko, Wan-Yu Chen, Yu-Ling Chang, Hsiu-Ting Lin and Han-Chung Wu. (2021) Monoclonal Antibodies against Nucleocapsid Protein of SARS-CoV-2 Variants for Detection of COVID-19. International Journal of Molecular Science. 22, 12412. https://doi.org/10.3390/ijms222212412
3. Kang-Hao Liang; Pao-Yin Chiang; Shih-Han Ko; Yu-Chi Chou; Ruei-Min Lu; Hsiu-Ting Lin; Wan-Yu Chen; Yi-Ling Lin; Mi-Hua Tao; Jia-Tsrong Jan; Han-Chung Wu. (2021) Antibody cocktail effective against variants of SARS-CoV-2. Journal of Biomedical Science. 28, 80 https://doi.org/10.1186/s12929-021-00777-9 PMID: 34814920
4. Su, S.-C.; Yang, T.-J.; Yu, P.-Y.; Liang, K.-H.; Chen, W.-Y.; Yang, C.-W.; Lin, H.-T.; Wang, M.-J.; Lu, R.-M.; Tso, H.-C.; Chung, M.-J.; Hsieh, T.-Y.; Chang, Y.-L.; Lin, S.-C.; Hsu, F.-Y.; Ke, F.-Y.; Wu, Y.-H.; Hwang, Y.-C.; Liu, I. J.; Liang, J.-J.; Liao, C.-C.; Ko, H.-Y.; Sun, C.-P.; Wu, P.-Y.; Jan, J.-T.; Chang, Y.-C.; Lin, Y.-L.; Tao, M.-H.; Hsu, S.-T. D.; Wu, H.-C. (2021) Structure-guided antibody cocktail for prevention and treatment of COVID-19. PLOS Pathogens 17, (10), e1009704. doi: 10.1371/journal.ppat.1009704 PMID: 34673836
5. Ruei-Min Lu., Wu CH, Patil A.V., Wu, H.C. (2020) Chapter 23: Peptide Targeting Methods. Handbook of In Vivo Chemistry in Mice: From Lab to Living System. WILEY-VCH Book, ISBN 9783527344321. (Invited review article) https://doi.org/10.1002/9783527344406.ch16
6. Ruei-Min Lu, Yu-Chyi Hwang, I-Ju Liu, Chi-Chiu Lee, Han-Zen Tsai, Hsin-Jung Li, Han-Chung Wu. (2020) Development of therapeutic antibodies for the treatment of diseases. Journal of Biomedical Science. 27, 1 (Invited review article)
7. Ruei-Min Lu, Chiu CY, Liu IJ, Chang YL, Liu YJ, Wu HC. (2019) Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer. Cancer Science. 110, 3773-3787. doi: 10.1111/cas.14208 PMID: 31578782
8. Lo, W.L., Liang, C.H., Chen, L.C., Lee, S.Y., Lo, S.N., Chen, M.W., Ruei-Min Lu, Liu, I.J., Wu, H.C., Chang, C.H. (2020) Imaging, biodistribution and efficacy of radiolabeled SP90 peptide in BT-483 tumor bearing mice. Applied Radiation and Isotopes. 161, 109162. PMID: 332561130
9. Wu, C. H., Liu, I. J., Ruei-Min Lu., Wu, H. C. (2016). Advancement and applications of peptide phage display technology in biomedical science. Journal of biomedical science. 23, 8. (Invited review article) PMID: 26786672
10. Liao, M. Y., Lai, J. K., Kuo, M. Y. P., Ruei-Min Lu, Lin, C. W., Cheng, P. C., Liang, K. H., Wu, H. C. (2015). An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget 6, 16253-16270. PMID: 26317650
11. De-Kuan Chang, Pi-Chun Li, Ruei-Min Lu, Wann-Neng Jane, Han-Chung Wu (2013) Peptide-Mediated Liposomal Doxorubicin Enhances Drug Delivery Efficiency and Therapeutic Efficacy in Animal Models. PLoS ONE 8, e83239. PMID: 24386166
12. Ruei-Min Lu, Min-Shan Chen, De-Kuan Chang, Chien-Yu Chiu, Wei-Chuan Lin, Shin-Long Yan, Yi-Ping Wang, Yuan-Sung Kuo, Albert Lo, and Han-Chung Wu. (2013) Targeted drug delivery systems mediated by a novel peptide in breast cancer therapy and imaging. PLoS ONE 8, e66128. PMID: 23776619
13. Cheng-Der Wu, Hung-Wen Chou, Yuan-Sung Kuo, Ruei-Min Lu, Yu-Chyi Hwang, Han-Chung Wu, Chin-Tarng Lin. (2012) Nucleolin antisense oligodeoxynucleotides induce apoptosis and may be used as a potential drug for nasopharyngeal carcinoma therapy. Oncology Reports 27, 94-100. PMID: 21956494
14. Ruei-Min Lu, Yu-Ling Chang, Min-Shan Chen and Han-Chung Wu. (2011) Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265-3274. PMID: 21306768
15. Ruei-Min Lu＊, Tung-Ying Lu＊, Mei-Ying Liao, John Yu, Chu-Hung Chung, Cheng-Fu Kao, and Han-Chung Wu. (2010) Epithelial Cell Adhesion Molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. The Journal of Biological Chemistry, 285, 8719-8732. (*Co-First Author) PMID: 20064925
16. Hung-Hsi Chen, Jan-Growth Chang, Ruei-Min Lu, Tsui-Yi Peng, and Woan-Yuh Tarn. (2008) The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Molecular and Cellular Biology, 28, 6929-6938. PMID: 18794368
17. Ruei-Min Lu＊, Kai-Ti Lin＊, and Woan-Yuh Tarn. (2004) The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo. Molecular and Cellular Biology, 24, 9176-9185. (*Co-First Author) PMID: 15456888
獲證專利
1. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Singapore Patent, WO/2016/168159, 2020/12/03~2036/04/12
2. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy. Canada Patent, CA2981883C, 2019/10/22~2036/04/12
3. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. 抗血管新生及び標的がん療法のための抗VEGFR2ヒト抗体. Japan Patent, JP特許6542383B2, 2019/07/10~-2039/04/12
4. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody and methods of use thereof for detecting VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing cancer cell cytotoxicity. U.S. Patent, US10196447B2, 2019/02/05~2036/04/12.
5. Han-Chung Wu, Ruei-Min Lu, Chiung-Yi Chiu, I-Ju Liu and Yu-Ling Chang. Anti-VEGFR2 human antibody for anti-angiogenic and targeted cancer therapy. Taiwan Patent, I621629, 2018/04/21~2036/04/12
6. Han-Chung Wu and Ruei-Min Lu. 抗ｃ−ｍｅｔ抗体及びその使用方法. Japan Patent, JP5955322B2, 2016/7/20~2031/08/30.
7. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. Taiwan Patent, I523867, 2016/03~2034/09.
8. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. European Union Patent, EP2611928, 2016/03~2031/09.
9. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. U.S. Patent, US9150655, 2015/10~2032/02.
10. Han-Chung Wu and Ruei-Min Lu. Anti-c-met antibody and methods of use thereof. China Patent, CN103415619B, 2015/10~2031/08.
11. Han-Chung Wu, Tung-Ying Lu, Cheng-Fu Kao, John Yu and Ruei-Min Lu, and Mei-Ying Liao. EpCAM as a reprograming factor for non-pluripotent cells. U.S. Patent, US8709806, 2014/04~2032/03